MIGDAL HA'EMEQ, Israel, June 23, 2014 – Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today the launch of Omega PC™, a new, premium fish oil-based omega-3 product.
Omega PC™ is a wild, cold fish extract, containing omega-3 fatty acids bound to phospholipids (PL) and triglycerides (TG). The first commercial sale of this innovative product took place last week in preparation for customer launch.
“We are very pleased with the launch of Omega PC™ and believe this will take us one step further towards creating a new golden standard for fish oil consumption,” said Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec Ltd. “Our strategic partnership with Polar Omega enables two significant players in the global omega-3 market to create a product that will deliver new health benefits to consumers. We believe that this new advanced fish oil product should help drive growth in the Omega 3 fish oil market, which became stagnant due to commoditization and lack of innovation.”
Omega PC™ offers the following benefits compared to current omega-3 fish oil:
· Omega-3 fatty acids bound to phospholipids that have been shown to be absorbed better than triglyceride bound Omega-3
· Better absorption leads to better efficacy and to higher accumulation of omega-3 fatty acids in target organs
· The omega-3 oil in Omega PC™ better represents the omega-3 oil in wild cold water fish as it contains omega 3 fatty acids bound to both TG and phospholipids.
· Reduced fishy burps.
The production of Omega PC™ follows the strictest sustainability protocols of the International Fishmeal and Fish Oil Organization (IFFO).
About Enzymotec Ltd.
Enzymotec Ltd. is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio- active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.